Literature DB >> 28106257

Limitations of polyethylene glycol-induced precipitation as predictive tool for protein solubility during formulation development.

Melanie Hofmann1,2, Matthias Winzer2, Christian Weber2, Henning Gieseler3.   

Abstract

OBJECTIVE: Polyethylene glycol (PEG)-induced protein precipitation is often used to extrapolate apparent protein solubility at specific formulation compositions. The procedure was used for several fields of application such as protein crystal growth but also protein formulation development. Nevertheless, most studies focused on applicability in protein crystal growth. In contrast, this study focuses on applicability of PEG-induced precipitation during high-concentration protein formulation development.
METHODS: In this study, solubility of three different model proteins was investigated over a broad range of pH. Solubility values predicted by PEG-induced precipitation were compared to real solubility behaviour determined by either turbidity or content measurements. KEY
FINDINGS: Predicted solubility by PEG-induced precipitation was confirmed for an Fc fusion protein and a monoclonal antibody. In contrast, PEG-induced precipitation failed to predict solubility of a single-domain antibody construct. Applicability of PEG-induced precipitation as indicator of protein solubility during formulation development was found to be not valid for one of three model molecules.
CONCLUSIONS: Under certain conditions, PEG-induced protein precipitation is not valid for prediction of real protein solubility behaviour. The procedure should be used carefully as tool for formulation development, and the results obtained should be validated by additional investigations.
© 2017 Royal Pharmaceutical Society.

Entities:  

Keywords:  formulation development; high-concentration protein formulations; polyethylene glycol; protein solubility

Mesh:

Substances:

Year:  2017        PMID: 28106257     DOI: 10.1111/jphp.12699

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  Development of a high-throughput solubility screening assay for use in antibody discovery.

Authors:  Qing Chai; James Shih; Caroline Weldon; Samantha Phan; Bryan E Jones
Journal:  MAbs       Date:  2019-03-26       Impact factor: 5.857

3.  Revisit PEG-Induced Precipitation Assay for Protein Solubility Assessment of Monoclonal Antibody Formulations.

Authors:  Martha J Scannell; Matthew W Hyatt; Ivan L Budyak; Mahlet A Woldeyes; Ying Wang
Journal:  Pharm Res       Date:  2021-10-13       Impact factor: 4.200

4.  Application of short hydrophobic elastin-like polypeptides for expression and purification of active proteins.

Authors:  Chun-Guang Yang; Ming-Fei Lang; Xin Fu; Heng Lin; Li-Chao Zhang; Gao-Shun Ge; Jing Sun; Xue-Jun Hu
Journal:  3 Biotech       Date:  2020-03-04       Impact factor: 2.406

5.  Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

Authors:  Marc Bailly; Carl Mieczkowski; Veronica Juan; Essam Metwally; Daniela Tomazela; Jeanne Baker; Makiko Uchida; Ester Kofman; Fahimeh Raoufi; Soha Motlagh; Yao Yu; Jihea Park; Smita Raghava; John Welsh; Michael Rauscher; Gopalan Raghunathan; Mark Hsieh; Yi-Ling Chen; Hang Thu Nguyen; Nhung Nguyen; Dan Cipriano; Laurence Fayadat-Dilman
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 6.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.